CORDIS · 190185443 · HORIZON

ProSCAN Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning

Coordinator: GLYCANOSTICS SRO (SK)

Prostate cancer (PCa) is the 2nd most frequent cancer in men with 1.4M new annual cases and nearly 0.4M deaths worldwide in 2020. PCa incidence is expected to increase to 2.1M cases and 0.6M annual deaths by 2035. Statistically, 1 in 8 men will get PCa in their lifetime. However, nearly 50% of cancer deaths may be avoided if PCa were detected at early stages. Survival is proportional to the stage reached at the time of diagnosis - hence early-stage diagnostics is key to reduce mortality. Our aim is to clinically validate & register ProSCAN, an affordable, non-invasive next-generation liquid b…

EU contribution
€2.0M
Total cost
€2.8M
Period
2021-10-01 → 2024-02-29
Framework
Horizon Europe (2021–2027)
Funding scheme
HORIZON-EIC-ACC-BF
Call
HORIZON-EIC-2021-ACCELERATORCHALLENGES-01
Status
CLOSED

About Horizon Europe (2021–2027)

Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.

Co-funding: the European Union contributes €2.0M toward a total project budget of €2.8M — a funding rate of 70%, with the remainder covered by the consortium partners. The project runs over approximately 2.4 years from 2021-10-01 to 2024-02-29.

Full record on CORDIS — partners, deliverables, publications, news.

Open on cordis.europa.eu → Grant DOI ↗

Frequently asked questions

Who funds this research project?
This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-EIC-ACC-BF funding scheme.
What is the EU contribution?
The European Commission contributes €2.0M toward a total project budget of €2.8M.
Which EU programme funds it?
The project is funded under Horizon Europe (2021–2027), call HORIZON-EIC-2021-ACCELERATORCHALLENGES-01.
Who coordinates the project?
The project is coordinated by GLYCANOSTICS SRO (SK).
What is the project timeline?
The project runs from 2021-10-01 to 2024-02-29 — approximately 2.4 years.
Where can I find the full project record?
The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 190185443.